消息面上，君实生物发布公告，近日，公司产品重组人源化抗IL-17A单克隆抗体(代号：JS005)在治疗 中重度斑块状银屑病的一项多中心、随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究(研究 编号： JS005-005-III-PsO)中取得阳性结果，共同主要研究终点和关键次要终点均具有统计学显著性和 临床意义的改善。公司计划将于近期向监管部门递交该产品的上市许可申请。 君实生物(01877)拉升逾9%，截至发稿，涨8.36%，报38.36港元，成交额1.73亿港元。 研究结果显示，与安慰剂相比，JS005可显著改善参与者的银屑病皮损面积和严重程度，达到sPGA评分 为0或1的参与者比例显著优于安慰剂，并在中重度斑块状银屑病参与者中安全性良好，相关研究结果计 划在未来国际学术会议上予以公布。 据介绍，JS005是公司自主研发的特异性抗IL-17A单克隆抗体。截至本公告披露日，JS005此项多中心、 随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究(研究编号：JS005-005-Ⅲ-PsO)已顺利完 成，并达到共同主要研究终点和关键次要终点。 ...

君实生物(01877)拉升逾9%，截至发稿，涨8.36%，报38.36港元，成交额1.73亿港元。 据介绍，JS005是公司自主研发的特异性抗IL-17A单克隆抗体。截至本公告披露日，JS005此项多中心、 随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究(研究编号：JS005-005-Ⅲ-PsO)已顺利完 成，并达到共同主要研究终点和关键次要终点。 研究结果显示，与安慰剂相比，JS005可显著改善参与者的银屑病皮损面积和严重程度，达到sPGA评分 为0或1的参与者比例显著优于安慰剂，并在中重度斑块状银屑病参与者中安全性良好，相关研究结果计 划在未来国际学术会议上予以公布。 消息面上，君实生物发布公告，近日，公司产品重组人源化抗IL-17A单克隆抗体(代号：JS005)在治疗 中重度斑块状银屑病的一项多中心、随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究(研究 编号：JS005-005-III-PsO)中取得阳性结果，共同主要研究终点和关键次要终点均具有统计学显著性和临 床意义的改善。公司计划将于近期向监管部门递交该产品的上市许可申请。 ...

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a high level of financing and short-selling activity, which may suggest investor sentiment and market dynamics [1] - On September 8, Junshi Biosciences experienced a decline of 0.98% in stock price, with a trading volume of 867 million yuan. The net financing purchase on that day was 15.66 million yuan, with a total financing and securities lending balance of 1.307 billion yuan [1] - The financing balance of Junshi Biosciences reached 1.296 billion yuan, accounting for 3.56% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high financing level [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the first half of 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] - As of June 30, 2025, the number of shareholders of Junshi Biosciences increased by 5.88% to 31,200, while the average circulating shares per person decreased by 5.56% to 24,543 shares [2] Group 3 - As of June 30, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares from the previous period, while the E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [3] - Hong Kong Central Clearing Limited ranked as the tenth largest circulating shareholder with 13.1291 million shares, a decrease of 186,650 shares compared to the previous period [3]

证券时报·数据宝统计显示，君实生物-U今日收盘价为47.53元，下跌0.98%，日换手率为2.36%，成交额 为8.67亿元，全天主力资金净流入928.17万元，近5日该股累计上涨0.89%，近5日资金合计净流入870.28 万元。 两融数据显示，该股最新融资余额为12.80亿元，近5日减少246.53万元，降幅为0.19%。（数据宝） 9月8日君实生物-U大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘折 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 100.00 | 4720.00 | 47.20 | -0.69 | 方正证券股份有 | 中信证券股份有限公司上海浦东 | | | | | | 限公司总部 | 新区东方路证券营业部 | 君实生物-U9月8日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4720.00万元，大宗交易 成交价为47.20元，相对今日收盘价折价0.69%。该笔交易的买方营业部为方正证 ...

Group 1 - On September 8, Junshi Biosciences executed a block trade of 1 million shares, with a transaction value of 47.2 million yuan, accounting for 5.16% of the total trading volume on that day [1][2] - The transaction price was 47.2 yuan per share, which represents a discount of 0.69% compared to the market closing price of 47.53 yuan [1]

9月8日，君实生物跌0.98%，成交额8.67亿元，换手率2.36%，总市值487.99亿元。 来源：新浪证券-红岸工作室 异动分析 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-731.10万，占比0.01%，行业排名40/54，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入1433.62万，连续2日被主力资金增仓。 区间今日近3日近5日近10日近20日主力净流入-731.10万1176.17万-252.62万-1.67亿-2.40亿 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.82亿，占总成交额的4.46%。 技术面：筹码平均交易成本为40.16元 创新药+生物疫苗+猴痘概念 1、2024年年报，公司具备完整的从创新药物的发现和开发、 在全球范围内的临床研究、 大规模生产到 商业化的全产业链能力， 旨在成为立足中国、 布局全球的创新医药公司。 公司坚持质量为本、 求真务 实、 诚信合规、 追求卓越的企业价值观， 致力于通过源头创新以及合作开发等形式来研发 first-in-class （同类首创）或 best-in- ...

Core Insights - Company Junshi Biosciences announced positive results from a Phase III clinical trial of its recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) for the treatment of moderate to severe plaque psoriasis, achieving both primary and key secondary endpoints with statistical significance and clinical relevance [1][2] - The company plans to submit a marketing authorization application to regulatory authorities in the near future for JS005 [1] Group 1 - JS005 is a specific anti-IL-17A monoclonal antibody developed by the company, targeting IL-17A, a cytokine associated with autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis [1] - The mechanism of JS005 involves high-affinity binding to IL-17A, selectively blocking its interaction with receptors IL-17RA/IL-17RC, thereby inhibiting downstream signaling pathways and the release of inflammatory factors [1] Group 2 - As of the announcement date, the Phase III clinical trial for JS005 in moderate to severe plaque psoriasis has met its primary and key secondary endpoints, while the Phase II clinical trial for active ankylosing spondylitis has completed primary endpoint visits and entered an extended treatment phase [2]

Core Insights - The company is actively expanding sales channels for its commercialized products beyond Toripalimab, focusing on enhancing revenue generation [1][2] - The management has outlined a clear strategy for business development, emphasizing collaboration and resource integration [2] Group 1: Product Commercialization - Mindewei® (Dexamethasone Hydrochloride Tablets) received conditional approval from the National Medical Products Administration in January 2023 and has achieved full-channel coverage by mid-2025, partnering with major e-commerce platforms and pharmacies [1] - Junmaikang® (Adalimumab) has eight approved indications and is included in the national medical insurance directory, with promotion managed by Maiwei Biotech [1] - Junshida® (Ongokrezi Monoclonal Antibody) was approved in October 2024 with three approved indications, and its commercialization is being advanced by partner Bochuang Pharmaceuticals [1] Group 2: Business Development Strategy - The company's business development team is actively pursuing connections between its pipeline and domestic and international resources, engaging in in-depth research and communication on multiple potential collaboration directions [2] - The company maintains an open and proactive attitude towards various types of business cooperation and aims to accelerate pipeline research and development [2] - Regular reviews of the pipeline will be conducted to identify candidates with business development potential and share innovative results promptly [2]

民得维®于2023年1月获得国家药品监督管理局附条件批准上市后，公司积极组建商业化团队，不断探 索销售模式。2025年上半年，民得维®实现全渠道覆盖，完成在美团、京东、阿里健康等药品零售电商 平台上线，与全国级医药公司及连锁药店达成战略合作，积极探索社区和县域市场医疗合作模式，帮助 患者更便捷的接受诊疗。 君迈康®目前共有8项适应症获批上市，并已全部纳入国家医保目录。根据公司与迈威生物的合作协 议，迈威生物或其控股子公司负责对君迈康®进行推广。 君适达®于2024年10月获批，目前共有三项适应症获批上市。公司合作伙伴博创医药正积极推进君适达 ®在中国大陆的后续商业化工作。 9月8日，君实生物举办2025半年度业绩说明会。会上有投资者提问，特瑞普利单抗之外，公司其他3款 款已实现商业化上市的产品如何为公司持续造血。公司现阶段在 BD 策略上是否有明确的规划或预期。 对此，管理层回应，特瑞普利单抗以外，公司及合作伙伴亦积极拓宽其他商业化产品的销售渠道。民得 维®（氢溴酸氘瑞米德韦片）、阿达木单抗（ 商品名： 君迈康®）、昂戈瑞西单抗（ 商品名： 君适达 ®）现阶段商业化进展如下： （上证路演） (编辑：林辰) 管 ...

9月8日，君实生物盘中下跌2.00%，截至10:54，报47.04元/股，成交5.81亿元，换手率1.58%，总市值 482.95亿元。 君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：中盘、融资融券、 增持回购、H股、猴痘概念等。 截至6月30日，君实生物股东户数3.12万，较上期增加5.88%；人均流通股24543股，较上期减少5.56%。 2025年1月-6月，君实生物实现营业收入11.68亿元，同比增长48.64%；归母净利润-4.13亿元，同比增长 36.01%。 机构持仓方面，截止2025年6月30日，君实生物十大流通股东中，华夏上证科创板50成份ETF （588000）位居第六大流通股东，持股2971.67万股，相比上期减少53.67万股。易方达上证科创板 50ETF（588080）位居第七大流通股东，持股2221.32万股，相比上期增加63.00万股。香港中央结算有 限公司位居第十大流通股东，持股1312.91万股，相比上期减少186.65万股。 资金流向方面，主力资金净流出1140.50万元，特大单买入5998.46万元，占比10.32%，卖出5474.26万 元 ...